Stifel analyst Thomas Stephan lowered the firm’s price target on RxSight (RXST) to $9 from $10 and keeps a Hold rating on the shares. The firm updated models across its medical technology and supplies coverage following Q4 reporting from the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST: